IntraOp secures 19th Mobetron order worldwide

SUNNYVALE, Calif. (BUSINESS WIRE) July 26, 2006 IntraOp Medical Corporation (OTCBB: IOPM) has received an order for its first Mobetron System in China. It will be the fourth Mobetron acquired by a hospital in Asia, and the 19th worldwide.

The Mobetron is an FDA-approved, easily transportable electron-beam instrument designed for intraoperative electron radiation therapy (IOERT), or the direct application of radiation to a tumor while a patient is undergoing cancer surgery. This first Chinese order will be installed at Beijing Tumor Hospital, China's premier cancer research and treatment center, often called the "National Cancer Institute of China," and a part of Beijing University Medical Center. In addition to treating patients, the hospital will use the Mobetron to train other Chinese practitioners in the use of IOERT and develop and expand the use of IOERT throughout China.

'Working with Beijing Tumor Hospital is a noteworthy opportunity for IntraOp Medical, the Mobetron and IOERT in general. Not only does this institution influence other cancer programs in China, it also has outstanding clinical research facilities,' said Dr. Donald Goer, President and Chief Executive Officer of IntraOp. 'We are expecting the Tumor Hospital to take an active role in coordinating IOERT studies throughout the Far East.'

Dr. Peter Yu, IntraOp's Director of Far East Operations, said: "We have been working diligently to place a Mobetron at this prestigious center. Many other cancer hospitals in China will be watching to see how well the Mobetron integrates with Beijing Tumor Hospital's cancer program, and we expect other hospitals to follow its lead. From my discussions with the Tumor Hospital staff, I have learned that, in addition to the treatment of advanced and recurrent disease, which is typical of centers with IOERT capability, this hospital will use the Mobetron to treat lung cancer and early-stage breast cancer as well."

About Beijing Tumor Hospital

Beijing Tumor Hospital is the teaching, research and treatment hospital of the Beijing University Medical School, focusing on the prevention, treatment and rehabilitation of cancer patients. With 400 beds, the institution treats 6,000 patients per year. In addition to a modern radiotherapy department, the center boasts one of the most advanced tumor molecular biology laboratories in the world.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.